Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on December 5, 2017, covering events occurring on November 29, 2017. The company is a Delaware corporation focused on clinical trials, specifically the ongoing LOCK IT 100 trial for its product Neutrolin.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a consulting fee rate of $800.00 per hour for Dr. Gary Gelbfish.
Material Changes
- Executive Appointment: Dr. Gary Gelbfish, a current director, was hired as a consultant to assist with the interim analysis of the LOCK IT 100 clinical trial.
- Compensation: Dr. Gelbfish will be paid $800.00 per hour for services rendered starting November 10, 2017.
- Board Composition: Due to the new consulting role, Dr. Gelbfish resigned from the Audit Committee. Myron Kaplan was appointed to replace him on the Audit Committee.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, general outlook statements, or specific risk factors beyond the operational change regarding the clinical trial analysis. The appointment of a director as a paid consultant is a standard disclosure under Item 5.02 regarding the departure of directors from specific committees.
Investor Verification Checklist
- Verify the total estimated cost of Dr. Gelbfish's consulting services for the interim analysis.
- Confirm the qualifications and background of Myron Kaplan, the new Audit Committee member.
- Review the status and timeline of the LOCK IT 100 clinical trial for Neutrolin in subsequent filings.
- Check for any related party transaction disclosures regarding the consulting agreement.